AstraZeneca Joins Rival to Develop New TB Treatment
March 15, 2011
The newly formed More Medicines for Tuberculosis (MM4TB) consortium aims to develop more effective and shorter-course TB treatments for the global marketplace.
MM4TB is being funded by a €16 million (US $22.3 million) European Union grant. The effort joins drug maker AstraZeneca and French rival Sanofi-Aventis; the Ecole Polytechnique Federale de Lausanne; the universities of Cambridge, Pavia (Italy) and Uppsala (Sweden); and other entities. It will be led by EPFL professor Stuart Cole, a TB expert.
The Guardian (London)
03.03.2011; Julia Kollewe
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)